Document is current
Any future updates will be listed below
-
Authors
Wang, Xuefeng
Tao, Ranran
Li, Tingyi
Lee, Sandra J
Eljilany, Islam
Streicher, Howard
Storkus, Walter J
Karunamurthy, Arivarasan D
Kirkwood, John M
Tarhini, Ahmad A
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01274338 at ClinicalTrials.govDocuments that mention this clinical trial
156 A novel polygenic risk score predicts immune checkpoint inhibitor-mediated dermatitis in a North American high-risk melanoma patient population
https://doi.org/10.1136/jitc-2025-sitc2025.0156
Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males
https://doi.org/10.1186/s12967-022-03450-3
45 An integrative immune signature of complementary circulating and tumoral biomarkers maximizes the predictive power of adjuvant immunotherapeutic benefits for high-risk melanoma
https://doi.org/10.1136/jitc-2023-sitc2023.0045
137 Tertiary lymphoid structure signature in digital H&E slides as a prognostic biomarker in cutaneous melanoma
https://doi.org/10.1136/jitc-2024-sitc2024.0137
- License Information
